{"id":836300,"date":"2026-09-17T13:27:03","date_gmt":"2026-09-17T13:27:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=836300"},"modified":"2026-09-17T13:27:03","modified_gmt":"2026-09-17T13:27:03","slug":"bone-neoplasms-market-steady-growth-driven-by-rising-incidence-and-advancing-precision-oncology-pipeline-through-2036","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bone-neoplasms-market-steady-growth-driven-by-rising-incidence-and-advancing-precision-oncology-pipeline-through-2036_836300.html","title":{"rendered":"Bone Neoplasms Market: Steady Growth Driven by Rising Incidence and Advancing Precision Oncology Pipeline Through 2036"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1789619449.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bone Neoplasms Market: Steady Growth Driven by Rising Incidence and Advancing Precision Oncology Pipeline Through 2036\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1789619449.jpg\" alt=\"Bone Neoplasms Market: Steady Growth Driven by Rising Incidence and Advancing Precision Oncology Pipeline Through 2036\" width=\"225\" height=\"124\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, New York) &ndash; 17th Sep 2026<\/strong> &ndash;&nbsp;DelveInsight&#8217;s &#8220;Bone Neoplasms Market Insights, Epidemiology, and Market Forecast &ndash; 2036&#8221; report delivers an in-depth understanding of bone neoplasms, covering historical and forecasted epidemiology, current treatment practices, market trends, and emerging therapies across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">To learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bone-neoplasms-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">Bone Neoplasms Market<\/a>, epidemiology trends, treatment landscape, and forecast outlook<\/p>\n<p style=\"text-align: justify;\">Key Highlights of the Bone Neoplasms Market<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The bone neoplasms market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period 2026&ndash;2036, propelled by rising global incidence of primary and metastatic bone cancers, an aging patient population, growing adoption of targeted biologics and precision oncology therapies, and increased R&amp;D investment in immunotherapy, antibody-drug conjugates, and molecularly targeted agents.<\/p>\n<\/li>\n<li>\n<p>Denosumab (XGEVA) and zoledronic acid (ZOMETA) remain cornerstone therapies, with the availability of denosumab biosimilars and generic zoledronic acid products increasing market competition and patient access.<\/p>\n<\/li>\n<li>\n<p>A gap remains for a single intervention delivering both rapid disease control and durable long-term remission across osteosarcoma, Ewing sarcoma, and chondrosarcoma, with minimal systemic adverse effects.<\/p>\n<\/li>\n<li>\n<p>Leading companies developing therapies for bone neoplasms include Amgen, Novartis, GSK, Pfizer, Esteve Pharmaceuticals, Hansoh Pharmaceutical Group, MedPacto, and others.<\/p>\n<\/li>\n<li>\n<p>GSK and Hansoh Pharmaceutical Group&#8217;s investigational antibody-drug conjugate risvutatug rezetecan is being evaluated for osteosarcoma through GSK&#8217;s global EMBOLD clinical development program.<\/p>\n<\/li>\n<li>\n<p>Key Bone Neoplasms Companies: Amgen, Novartis, GSK, Pfizer, and more.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Bone Neoplasms Overview<\/p>\n<p style=\"text-align: justify;\">Bone tumors comprise a diverse group of neoplasms that may arise directly from bone (primary tumors) or result from the spread of cancer from other organs (secondary\/metastatic tumors). Major malignant primary bone tumors include osteosarcoma, the most common form, which primarily affects adolescents and young adults and typically develops in long bones; Ewing&#8217;s sarcoma, an aggressive tumor seen mainly in children and young adults; and chondrosarcoma, a cartilage-forming malignancy that occurs more frequently in adults. The occurrence of bone tumors is influenced by age, gender, geographic variation, and genetic susceptibility, including IDH1\/IDH2 mutations linked to chondrosarcoma subtypes, with osteosarcoma showing a characteristic bimodal age distribution during adolescence and later adulthood.<\/p>\n<p style=\"text-align: justify;\">The report provides a comprehensive overview of the disease, including its diagnosis and treatment algorithms, across the United States, EU4, the UK, and Japan.<\/p>\n<p style=\"text-align: justify;\">Gain access to detailed country-wise epidemiology, diagnosed patient population forecasts, treatment algorithms, and market size projections for Bone Neoplasms across the US, EU4, UK, and Japan:<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bone-neoplasms-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\"> https:\/\/www.delveinsight.com\/report-store\/bone-neoplasms-market<\/a><\/p>\n<p style=\"text-align: justify;\">Bone Neoplasms Epidemiology Insights<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s report analyzes historical, current, and forecasted epidemiology trends for bone neoplasms across the seven major markets during the 2022&ndash;2036 study period.<\/p>\n<p style=\"text-align: justify;\">The epidemiology assessment includes:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total incident cases of bone neoplasms.<\/p>\n<\/li>\n<li>\n<p>Type-specific, age-specific, and gender-specific cases of bone neoplasms.<\/p>\n<\/li>\n<li>\n<p>Treated cases of bone neoplasms.<\/p>\n<\/li>\n<li>\n<p>Analysis based on published literature and key opinion leader (KOL) insights.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Key epidemiological findings referenced in the report include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>In the US, primary bone and joint cancers remain uncommon, with an estimated 4,110 new cases, representing only 0.2% of all new cancer diagnoses. Osteosarcoma is the most common subtype among children and adolescents, whereas chondrosarcoma predominates in adults.<\/p>\n<\/li>\n<li>\n<p>In the 7MM, there were approximately 1,200 and 900 cases of osteosarcoma in males and females respectively, with the higher male incidence attributed to differences in adolescent skeletal growth patterns.<\/p>\n<\/li>\n<li>\n<p>Malignant neoplasm of bone and articular cartilage (MNBAC) exhibits a bimodal age distribution, peaking in adolescents (10&ndash;14 years) and older adults (&gt;65 years), and is characterized by nonspecific early symptoms, local aggressiveness, and a high risk of pulmonary metastasis.<\/p>\n<\/li>\n<li>\n<p>A consistent male predominance has been observed in osteosarcoma, with a male-to-female ratio ranging from approximately 1.3:1 to 1.5:1. The lungs are the predominant metastatic site, accounting for roughly 90% of distant spread, and pulmonary metastases remain the leading cause of osteosarcoma-related mortality.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Bone Neoplasms Epidemiology Segmentation Covered in the Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Incident Cases of Bone Neoplasms<\/p>\n<\/li>\n<li>\n<p>Type-Specific Cases of Bone Neoplasms<\/p>\n<\/li>\n<li>\n<p>Age-Specific Cases of Bone Neoplasms<\/p>\n<\/li>\n<li>\n<p>Gender-Specific Cases of Bone Neoplasms<\/p>\n<\/li>\n<li>\n<p>Treated Cases of Bone Neoplasms<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Bone Neoplasms Treatment Landscape and Key CompaniesKey Bone Neoplasms Companies:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Amgen<\/p>\n<\/li>\n<li>\n<p>Novartis<\/p>\n<\/li>\n<li>\n<p>GSK<\/p>\n<\/li>\n<li>\n<p>Pfizer<\/p>\n<\/li>\n<li>\n<p>Esteve Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Hansoh Pharmaceutical Group<\/p>\n<\/li>\n<li>\n<p>MedPacto<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report includes clinical, regulatory, and commercial analysis of both approved therapies and investigational drugs. Current treatment approaches for primary bone cancer include surgery (wide excision for low-grade tumors, radical excision for high-grade tumors), chemotherapy (standard for osteosarcoma and Ewing sarcoma, limited role in chondrosarcoma except mesenchymal subtypes), and radiotherapy (particularly effective in radiosensitive Ewing sarcoma, with a palliative role across all primary bone cancers).<\/p>\n<p style=\"text-align: justify;\">Emerging Drug Uptake and Future Opportunities<\/p>\n<p style=\"text-align: justify;\">DelveInsight analyzes the anticipated uptake of recently approved and upcoming therapies expected to shape the market between 2022 and 2036.<\/p>\n<p style=\"text-align: justify;\">Mifamurtide (MEPACT) &ndash; Esteve Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Mifamurtide is indicated in children, adolescents, and young adults for high-grade resectable non-metastatic osteosarcoma following macroscopically complete surgical resection, used in combination with post-operative multi-agent chemotherapy. It is a fully synthetic derivative of muramyl dipeptide (MDP) with immunostimulatory, macrophage-stimulating activity, and received EU marketing authorization in March 2009.<\/p>\n<p style=\"text-align: justify;\">Risvutatug Rezetecan &ndash; GSK \/ Hansoh Pharmaceutical Group<\/p>\n<p style=\"text-align: justify;\">Also known as Ris-Rez, GSK5764227, and HS-20093, this investigational antibody-drug conjugate targets B7-H3, a cell-surface protein highly expressed in numerous solid tumors, delivering its cytotoxic payload directly to tumor tissue. It is in Phase II\/III development for osteosarcoma via IV infusion.<\/p>\n<p style=\"text-align: justify;\">Vactosertib &ndash; MedPacto<\/p>\n<p style=\"text-align: justify;\">Vactosertib is an oral TGF-&beta;1 kinase inhibitor in Phase I\/II development for osteosarcoma.<\/p>\n<p style=\"text-align: justify;\">Stay ahead of the evolving <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bone-neoplasms-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">bone neoplasms treatment landscape<\/a> with in-depth analysis of market opportunities and future commercial forecasts<\/p>\n<p style=\"text-align: justify;\">Bone Neoplasms Market Outlook<\/p>\n<p style=\"text-align: justify;\">The bone-neoplasms therapeutics market is expected to increase over the forecast period 2026&ndash;2036, driven by rising incidence, technological advancements, and upcoming therapies. In 2025, the US held a significant share of the overall 7MM bone-neoplasms market, primarily attributed to the country&#8217;s higher incidence of the condition and elevated treatment costs &mdash; a dominance projected to persist, especially with the potential early introduction of new products.<\/p>\n<p style=\"text-align: justify;\">Key Market Drivers<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Rising global incidence of primary and metastatic bone cancers.<\/p>\n<\/li>\n<li>\n<p>Aging patient population increasingly susceptible to skeletal malignancies.<\/p>\n<\/li>\n<li>\n<p>Growing adoption of targeted biologics and precision oncology therapies.<\/p>\n<\/li>\n<li>\n<p>Increased R&amp;D investment in immunotherapy, antibody-drug conjugates, and molecularly targeted agents.<\/p>\n<\/li>\n<li>\n<p>Improved diagnostic imaging enabling higher detection rates.<\/p>\n<\/li>\n<li>\n<p>Availability of denosumab biosimilars and generic zoledronic acid products expanding market competition and patient access.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Explore comprehensive insights into the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bone-neoplasms-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=mpr\">Bone Neoplasms Market<\/a><\/p>\n<p style=\"text-align: justify;\">Scope of the Bone Neoplasms Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Study Period: 2022&ndash;2036<\/p>\n<\/li>\n<li>\n<p>Historical Period: 2022&ndash;2025<\/p>\n<\/li>\n<li>\n<p>Base Year: 2025<\/p>\n<\/li>\n<li>\n<p>Forecast Period: 2026&ndash;2036<\/p>\n<\/li>\n<li>\n<p>Coverage: United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/p>\n<\/li>\n<li>\n<p>Key Bone Neoplasms Companies: Amgen, Novartis, GSK, Pfizer, Esteve Pharmaceuticals, Hansoh Pharmaceutical Group, MedPacto, and more.<\/p>\n<\/li>\n<li>\n<p>Bone Neoplasms Therapeutic Assessment: Current marketed and emerging therapies.<\/p>\n<\/li>\n<li>\n<p>Analysis Included: Epidemiology Forecast, Market Size and Growth Forecast, Market Size by Therapy, Current and Emerging Therapies, Competitive Landscape Assessment, SWOT Analysis, Conjoint Analysis, Unmet Needs Assessment, Key Opinion Leader (KOL) Insights, Reimbursement and Market Access Analysis, and Peak Patient Share Analysis.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">About DelveInsight<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare market research and business consulting firm dedicated exclusively to the life sciences industry. The company provides comprehensive market intelligence, competitive intelligence, epidemiology forecasting, commercial strategy, and healthcare consulting services that enable pharmaceutical, biotechnology, and medical device organizations to make informed strategic decisions, identify growth opportunities, and accelerate business success.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_98558.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Mehul Malhotra<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bone-neoplasms-market-steady-growth-driven-by-rising-incidence-and-advancing-precision-oncology-pipeline-through-2036\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>A-1  NV 89107<br \/><strong>City:<\/strong> delhi<br \/><strong>State:<\/strong> Indiana<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bone-neoplasms-market-steady-growth-driven-by-rising-incidence-and-advancing-precision-oncology-pipeline-through-2036\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Albany, New York) &ndash; 17th Sep 2026 &ndash;&nbsp;DelveInsight&#8217;s &#8220;Bone Neoplasms Market Insights, Epidemiology, and Market Forecast &ndash; 2036&#8221; report delivers an in-depth understanding of bone neoplasms, covering historical and forecasted epidemiology, current treatment practices, market trends, and emerging therapies across &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bone-neoplasms-market-steady-growth-driven-by-rising-incidence-and-advancing-precision-oncology-pipeline-through-2036_836300.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,417,419,406,420],"tags":[],"class_list":["post-836300","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Marketing-Sales","category-Media-Communications","category-Pharmaceuticals-Biotech","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/836300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=836300"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/836300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=836300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=836300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=836300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}